European Psychiatry
April 4, 2024
Haiyan Liu, Chengyu Wang, Xiaofeng Lan et al.
7 citations
Amygdala subregion-based network dysfunction has been determined to be centrally implicated in major depressive disorder (MDD). Little is known about whether ketamine modulates amygdala subarea-related networks. We aimed to investigate the relationships between changes in the resting-state functional connectivity (RSFC) of amygdala subregions and ketamine treatment and to identify important...
Journal of Magnetic Resonance Imaging
April 2024
Hao Li, Xunrong Luo, Kai Qi et al.
Ketamine is a quick acting antidepressant drug, and an accurate detection method is lacking. Ketamine's effects in a rat depression model have not previously been well explored using glutamate chemical exchange saturation transfer (GluCEST). To investigate the GluCEST changes of chronic unpredictable mild stress (CUMS) rats after receiving either ketamine or saline injection. Randomized animal...
European Psychiatry
April 1, 2024
Amanda M. Klassen, Caitlin Baten, J. H. Shepherd et al.
Introduction Major depressive disorder (MDD) is a tremendous global disease burden and the leading cause of disability worldwide. Unfortunately, individuals diagnosed with MDD typically experience a delayed response to traditional antidepressants and many do not adequately respond to pharmacotherapy, even after multiple trials. The critical need for novel antidepressant treatments has led to a...
BMJ Open
April 1, 2024
Shampa Maji, Debadatta Mohapatra, Monalisa Jena et al.
Background Therapeutic latency, lack of efficacy and adverse drug reactions are the major concerns in current antidepressant therapies. To overcome these treatment hurdles, add-on therapy to conventional antidepressant medications may lead to better therapeutic outcomes. The present randomised controlled trial has been planned to evaluate the efficacy and safety of add-on dextromethorphan to...
International Journal of Mental Health and Addiction
April 1, 2024
David T. Kryszajtys, Jacqueline L. Bender, Brian Rush et al.
2 citations
Little is known about how people decide to use psychedelics to self-treat depression and anxiety, though the practice is growing. We explored online community discussions of members’ decisions around self-treatment with psychedelics for depression or anxiety. We used constructivist grounded theory to select and analyze 98 members’ posts across 95 discussion threads (99, 552 words) and...
Current Psychiatry Reports
April 1, 2024
John L. Havlik, Syed Wahid, Kayla M Teopiz et al.
30 citations
Purpose of Review We review recent advances in the treatment of treatment-resistant depression (TRD), a disorder with very limited treatment options until recently. We examine advances in psychotherapeutic, psychopharmacologic, and interventional psychiatry approaches to treatment of TRD. We also highlight various definitions of TRD in recent scientific literature. Recent Findings Recent...
Nervenheilkunde
April 1, 2024
Eva Maria Schindowski, Franz X. Vollenweider
ZUSAMMENFASSUNG Der Artikel stellt 2 Behandlungsverläufe von Patienten mit rezidivierender Depression gegenüber, welche mit Psilocybin behandelt wurden. Weltweit wächst stetig die Anzahl Studien, die die Verwendung von Psilocybin zur Behandlung von Depressionen untersuchen und damit mehr und mehr das Interesse an dieser Therapieform. Während einige Kollegen aus dem Forschungsumfeld einen...
Fortschritte der Neurologie · Psychiatrie
April 1, 2024
Psilocybin ist ein Indolalkaloid aus der Gruppe der Tryptamine und wird zur Behandlung behandlungsresistenter Depressionen (TRD) untersucht. Da die Einnahme von Antidepressiva die psychedelische Wirkung von Psilocybin potenziell verändern kann, werden diese vor Studienbeginn regelhaft ausgeschlichen. Goodwin et al. dagegen wollten prüfen, ob Psilocybin eine SSRI-Therapie bereichern kann, und...
Verhaltenstherapie
April 1, 2024
Elisabeth A. Arens, Lucas Donnerstag, Stefan G Hofmann et al.
1 citation
In the course of the Covid-19 pandemic, it has become clear what relevance non-contact psychotherapeutic online interventions in mental health care could possibly have in the future. The present pilot study aims to test whether a Metta-based group program is also an acceptable and feasible treatment when conducted as video-based intervention. Metta meditations aim at showing unconditional...
Actas Españolas de Psiquiatría
April 1, 2024
Xiumei Li, Wei Gao, Jie Yu et al.
5 citations
Chronic kidney disease (CKD) patients may experience pessimism, and even despair, due to long-term nature of the condition, which increases the risk of depression. Mindfulness-based stress reduction (MBSR) can relieve depression. This retrospective cohort study aimed to investigate the effects of MBSR on mental health and quality of life in CKD patients with mild-to-moderate depression, so as...